INGELHEIM, Germany-Monday 15 October 2018 [ AETOS Wire ]
Corporate Communications
Media + PR
Meike Bausinger
Phone: +49 6132 77 182085
Mobile: +49 151 44061760
Fax: +49 6132 77 6601
Email: press@boehringer-ingelheim.com
- Data from key trials will aid in increasing scientific understanding of ESUS and CVT
- RESPECT-ESUS is first randomised trial to investigate clinical profile of Pradaxa® vs ASA
(BUSINESS WIRE) -- Boehringer Ingelheim today announced that primary results from two key trials, RE-SPECT ESUS® and RE-SPECT CVT®,
will be presented at the upcoming World Stroke Congress in Montreal,
Canada 17-20 October 2018. These primary analyses will contribute to the
scientific community’s understanding of both disease states and the
clinical profile of dabigatran etexilate (Pradaxa®).
The
results from RE-SPECT ESUS, the first randomised trial comparing
dabigatran etexilate with acetylsalicylic acid (ASA) in any indication,
will add further insight into the prevention of secondary stroke in
patients with an embolic stroke of undetermined source (ESUS).1 As
the first comparison to ASA, this trial will also offer further
important insights into the clinical profile of dabigatran etexilate.
RE-SPECT CVT will provide additional knowledge regarding treatment of patients with cerebral venous thrombosis (CVT).2 It
is the first exploratory, prospective, randomised controlled study of
any non-vitamin K antagonist oral anticoagulant (NOAC) in patients with
blood clots in the veins or venous sinuses of the brain.
Both
trials are part of Boehringer Ingelheim’s ongoing commitment to
expanding scientific knowledge of stroke prevention and form part of the
extensive RE-VOLUTION® clinical trial programme for dabigatran etexilate, which upon completion will have enrolled more than 60,000 patients worldwide.1-14
The results from these two trials will be presented in the following sessions:
|
Abstract title
|
|
Presentation details
|
|||||||
|
RE-SPECT ESUS: Dabigatran versus acetylsalicylic acid for stroke prevention
in patients with embolic stroke of undetermined source
|
Wednesday 17 October, 19:10 – 19:30, HALL A
Session code: AWA01
Session title: Opening: late-breaking trials
Presentation number: 100
|
||||||||
|
RE-SPECT CVT: Randomized controlled trial of the safety and efficacy
of dabigatran etexilate vs. dose-adjusted warfarin in patients with cerebral
venous thrombosis
|
Saturday 20 October, 11:30 – 11:50, HALL B
Session code: AWA03
Session title: Award lectures & late breaking trials
Presentation number: 101
|
Please click on the following link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/Results-from-two-Pradaxa-trials-to-be-presented-at-WSC
Intended audiences:
This
press release is issued from our Corporate Headquarters in Ingelheim,
Germany and is intended to provide information about our global
business. It is directed to the international audience outside
Germany. Please be aware that information relating to the approval
status and labels of approved products may vary from country to country,
and a country-specific press release on this topic may have been issued
in the countries where we do business.
Contacts
Boehringer IngelheimCorporate Communications
Media + PR
Meike Bausinger
Phone: +49 6132 77 182085
Mobile: +49 151 44061760
Fax: +49 6132 77 6601
Email: press@boehringer-ingelheim.com